ArticleFrontiers in oncology2026
Prognostic prediction model for triple-negative breast cancer using artificial intelligence and ultrasound radiomics.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate an artificial intelligence (AI)-driven ultrasound radiomics model for predicting postoperative recurrence and metastasis in patients with triple-negative breast cancer (TNBC) receiving standardized therapies. Methods: We conducted a retrospective study of 668 female TNBC patients (treated 2013-2018). Univariate and multivariate logistic regression were first used to screen significant clinicopathological variables for baseline assessment and to inform model development. Radiomic features were automatically extracted from pretreatment ultrasound images using PyRadiomics following tumor segmentation. A radiomics signature was constructed by integrating LASSO for feature selection with a support vector machine (SVM) classifier. The model's performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, decision curve analysis (DCA), and confusion matrices. Results: The ultrasound radiomics model showed high predictive accuracy for any recurrence/metastasis, with an AUC of 0.9458 in the training cohort and 0.8983 in the validation cohort. For distinguishing between locoregional recurrence and distant metastasis, the model achieved AUCs of 0.9341 and 0.8824 in the training and validation cohorts, respectively. Calibration and decision curve analyses confirmed the model's robust predictive capability and potential clinical utility. Conclusion: This study demonstrates that an AI-enhanced ultrasound radiomics model can effectively predict postoperative recurrence and metastasis patterns in TNBC, offering a promising non-invasive tool to support personalized prognosis assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.